Abstract

FORMULATION AND IN-VITRO EVALUATION OF FIXED DOSE COMBINATION OF ESCITALOPRAM AND CLONAZEPAM TABLET

P. Khandelwal, Vikran* and Nirav N.Patel

Abstract

An attempt was made to formulate, evaluate the fixed dose combination of Escitalopram-clonazepam tablet. The purpose of such formulation was to synergism the effect of such salts for the treatment of conditions which can used for that particular or with that drug aside. So this method of formulation can also reduce the burden of pills from the patients and risk involve in the side effects. Wet granulation method was employed for the formulation because by direct compression or with dry granulation the disintegration and the binding is not easy to achieve. Beside the active ingrediants of Escitalopram and Clonazepam, tablet contain Maize starch, Lactose, Microcrystalline cellulose, PVPK-30, Aerosil, Croscarmellose sodium, Purified talc and Magnesium stearate. Accelerated stability studies for selected formulation F1 and F3 showed physicochemical stability for a period of one month at 40°C / 75% RH.

Keywords: Fixed Dose Combination, Escitalopram, Clonazepam, Wet granulation.